Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MYMD PHARMACEUTICALS, INC.

(MYMD)
 SummaryQuotesChartsNewsCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/10/2021 09/13/2021 09/14/2021 09/15/2021 09/16/2021 Date
7.74(c) 7.02(c) 6.71(c) 6.79(c) 6.79 Last
331 751 211 217 119 469 114 323 149 538 Volume
+7.50% -9.30% -4.42% +1.19% 0.00% Change
More quotes
Estimated financial data (e) (USD)
Sales 2019 - - -
Net income 2019 -9,64 M - -
Net Debt 2019 0,87 M - -
P/E ratio 2019 -
Yield 2019 -
Sales 2020 - - -
Net income 2020 -8,93 M - -
Net Debt 2020 2,89 M - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 254 M 254 M -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 6
Free-Float 86,7%
More Financials
Company
MyMD Pharmaceuticals, Inc., formerly Akers Biosciences, Inc., is a clinical stage pharmaceutical company. The Company is focused on developing and commercializing two therapeutic platforms based on therapeutic targets, MYMD-1 and Supera-CBD. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis,... 
More about the company
All news about MYMD PHARMACEUTICALS, INC.
09/13MYMD PHARMACEUTICALS : Announces Fourth Quarter 2021 Initiation of Phase 2 Clini..
PU
09/13MYMD PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and ..
AQ
09/13MYMD PHARMACEUTICALS : Pharma to Start Mid-Stage -1 Trial to Delay Aging
MT
09/13MYMD PHARMACEUTICALS : Announces Fourth Quarter 2021 Initiation of Phase 2 Clini..
BU
09/13MyMD Pharmaceuticals, Inc. Announces Fourth Quarter 2021 Initiation of Phase ..
CI
09/09MYMD PHARMACEUTICALS : to Present its Novel Therapeutic Platforms for Extending ..
BU
09/03MYMD PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K..
AQ
09/03MyMD Pharmaceuticals, Inc.'s Board of Director Robert C. Schroeder Passes Awa..
CI
08/24MYMD PHARMACEUTICALS : Secures US Patent for Asthma, Fibrosis Treatment
MT
08/24MYMD PHARMACEUTICALS : Announces Issuance of U.S. Patent for Use of Lead Candida..
BU
08/16MYMD PHARMACEUTICALS : Management's Discussion and Analysis of Financial Conditi..
AQ
08/10MYMD PHARMACEUTICALS : Announces Issuance of U.S. Patent for Synthetic Cannabino..
BU
08/10MYMD PHARMACEUTICALS : Unit Oravax to Start Clinical Trials for Oral COVID-19 Va..
MT
08/10MYMD PHARMACEUTICALS : Subsidiary Oravax Medical Preparing to Commence Clinical ..
BU
08/05MYMD PHARMACEUTICALS : rsquo; Lead Compound MYMD-1 Shown to Suppress a Major Cau..
BU
More news
News in other languages on MYMD PHARMACEUTICALS, INC.
09/13MyMD Pharma va lancer l'essai de mi-étape MYMD-1 pour retarder le vieillissem..
More news
Chart MYMD PHARMACEUTICALS, INC.
Duration : Period :
MyMD Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MYMD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Managers and Directors
Christopher C. Chapman President, Director & Chief Medical Officer
Ian Rhodes Chief Financial Officer
Adam Kaplin Chief Scientific Officer
Paul Rivard Executive VP-Operations & General Counsel
Joshua Nathaniel Silverman Director
Sector and Competitors
1st jan.Capi. (M$)
MYMD PHARMACEUTICALS, INC.68.59%254
ABBOTT LABORATORIES16.44%226 016
MEDTRONIC PLC12.39%177 176
BECTON, DICKINSON AND COMPANY4.58%75 152
HOYA CORPORATION31.85%63 447
SARTORIUS STEDIM BIOTECH82.07%57 757